Issue of Equity

Issue of Equity

Eco Animal Health Group Plc

27 September 2011

Eco Animal Health Group plc ("Eco" or the "Company")

The following amendment has been made to the Issue of Equity announcement made on the 23^rd September 2011 at 11.38am under RNS number 0923005274.

The new shares, which will rank pari passu with the existing shares of the Company, are expected to be admitted to trading on 29 September 2011 and following these issues, the Company has 52,427,161 shares in issue and the following directors' shareholdings have increased.

	Â	Number of	Â	Shareholding	Â	Percentage
		Shares held		post scrip		shareholding
		prior to scrip				post scrip
P Lawrence & family		11,106,171		11,208,536		21.38
Executive Chairman
							Â
All other details remain unchanged.
The full amended text is shown below.

The Company announces that on 23 September 2011, 173,989 new Ordinary shares of 5p each were issued to shareholders who elected to receive new shares instead of cash for the interim dividend declared by the directors on 21 July 2011 and who held Ordinary shares on the record date of 19 August 2011. The new shares, which will rank pari passu with the existing shares of the Company, are expected to be admitted to trading on 29 September 2011.

Following these issues, the Company has 52,427,161 shares in issue and the following directors' shareholdings have increased.

	Â	Number of	Â	Shareholding	Â	Percentage
		Shares held		post scrip		shareholding
		prior to scrip				post scrip
							Â
P Lawrence & family		11,106,171		11,208,536		21.38
Executive Chairman
							Â
K Stockdale		7,987		8,051		0.01
Finance Director
							Â
D Danson		14,598		14,598		0.02
Non Executive Director

Enquires:

Eco Animal Health Group plc	Â
Peter Lawrence, Executive Chairman		020 8336 6190

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products. Our products for these global growth markets promote well-being in animals. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders.